HLA-haploidentical donor transplants with post-transplant cyclophosphamide in children with primary immune deficiency disorders-Reference-Cited by-同舟云学术

HLA-haploidentical donor transplants with post-transplant cyclophosphamide in children with primary immune deficiency disorders

Published:2022-02-04 Issue:4 Volume:57 Page:668-670
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

AlSaedi Hawazen^ORCID,Mohammed Reem^ORCID,Siddiqui Khawar,Al-Ahmari Ali^ORCID,AlSaud Bandar,Almousa Hamoud,Al-Jefri Abdullah,Ghemlas Ibrahim,AlAnazi Awatif,Al-Seraihy Amal^ORCID,El-Solh Hassan,Ayas Mouhab^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01589-7.pdf

Reference12 articles.

1. Porta F, Forino C, De Martiis D, Soncini E, Notarangelo L, Tettoni K, et al. Stem cell transplantation for primary immunodeficiencies. Bone Marrow Transp. 2008;41(Suppl 2):S83–86. https://doi.org/10.1038/bmt.2008.61. e-pub ahead of print 2008/07/24.

2. Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295. https://doi.org/10.3389/fped.2019.00295. e-pub ahead of print 2019/08/24.

3. Al-Seraihy A, Al-Saedi H, Al-Ahmari A, Ghemlas I, Ayas M T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis. Bone Marrow Transpl. 2021. https://doi.org/10.1038/s41409-021-01282-1. e-pub ahead of print 2021/04/08.

4. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47:65–77. https://doi.org/10.1007/s12026-009-8139-0. e-pub ahead of print 2010/01/13.

5. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6. https://doi.org/10.1200/JCO.2012.44.3523. e-pub ahead of print 2013/02/21.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Outcomes with Haploidentical Stem Cell Transplantation [HaploSCT] in Children Using Post-transplant Cyclophosphamide: a Single Center Experience;Indian Journal of Hematology and Blood Transfusion;2023-09-28

2. Progress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity;Current Opinion in Pediatrics;2023-09-21

3. Sulfated Polysaccharide Regulates the Homing of HSPCs in a BMP‐2‐Triggered In Vivo Osteo‐Organoid;Advanced Science;2023-06-25

4. An analysis of the efficacy of graft-versus-host disease prophylaxis with post-transplant cyclophosphamide in children with acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation from HLA-matched and partially-matched unrelated donors;Pediatric Hematology/Oncology and Immunopathology;2023-05-12